SO-CALLED “miracle” weight-loss jabs are far less effective in the real world than in clinical trials, a major study has revealed. The new findings could

AUSTIN, Texas–(BUSINESS WIRE)—- $IPA #AI–ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that

H. Armstrong Roberts/ClassicStock/Getty Images; BI Every generation has its own version of the vibrating belt machine — the ’50s-era contraption that promised to literally shake

Abstract Aims Obesity is a major risk factor for heart failure with mildly reduced or preserved ejection fraction (HFpEF). This meta-analysis of randomised clinical trials

Abstract Basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are available in two fixed-ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D),

coldsnowstorm/Getty Images Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a condition in which breathing stops and

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its

What You Should Know:  – LucyRx, an independent, next-generation pharmacy benefits manager (PBM), and Personify Health®, the company making healthier easier announced a strategic partnership

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total

Post Content

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers

Nonalcoholic fatty liver disease refers to a range of conditions in which fatty deposits occur in the liver. (Representational Image)Nonalcoholic fatty liver disease refers to

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite

Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric. Last month, Morgan Stanley

Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials  Cleveland Clinic Newsroom Real-World Use

Comments

DENVER–(BUSINESS WIRE)–Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, today released a report showing that people can maintain

By Dennis Thompson HealthDay ReporterWEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic,…

Omada Health’s president Wei-Li Shao and CEO Sean Duffy at the company’s June 6 IPO. Omada Health AI is taking over healthcare, but Omada Health

Nature, Published online: 11 June 2025; doi:10.1038/d41586-025-01770-0 Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side

GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment to help

Israeli foodtech startup Lembas has emerged from stealth with “GLP-1 Edge,” a bioactive peptide that triggers the production of GLP-1 and other gut hormones that

This was an interesting interview with Richard Saynor, the head of Sandoz (which is now an independent generics company). That’s a part of the industry

(MedPage Today) — Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in real-world settings versus what is

I’ve done plenty of DNA tests to help me explore my heritage a little deeper (I’m a hodgepodge of Eastern European, in case you’re wondering).

Teens are being prescribed Ozempic and similar drugs more than ever before — and some doctors are worried about what the trend could mean. In

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because

(MedPage Today) — CHICAGO — Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse events tied to blockbuster

The popularity of glucagon-like peptide-1 (GLP-1) receptor agonists continues, with use of tirzepatide and semaglutide surpassing that of traditional weight-lowering medications.

Amplifye, a UC Davis spinout led by former Amyris CEO John Melo, has launched its first product: a proprietary enzyme (P24) claimed to optimize protein

In 2024, the cost and utilization of specialty dermatology drugs significantly drove a 7% increase in pharmaceutical costs, according to a June 10 report from

Metsera’s drug shows potential in early clinical trial  statnews.com Weight-loss newbie Metsera says once-monthly amylin matches GLP-1 efficacy  FirstWord Pharma Obesity Startup Metsera Shares Rise on Early-Stage

DALLAS–(BUSINESS WIRE)–Pharmaceutical Strategies Group (“PSG”), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating

Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss

Weight-loss drugs continue to grow in popularity, with market researchers predicting that global demand for the medications could reach $150 billion by 2035. GLP-1 agonists

New findings about semaglutide and tirzepatide use from health records suggest lower overall weight loss but also factors that predict success. Medscape Medical News

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or